Precise Insights

Advanced Data and AI for Prostate Cancer

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo

 

labs

Results from variety of patient tests

Visits

Oncology practice visits

Observations

Tumor-related observations plus vitals, biometrics, pain, and more

Procedures

Surgeries, radiation, biopsies, imaging, chemotherapy, etc

Medications

Start and end dates, brand vs. generic codes, dosage, duration, and cycles

Diagnoses

Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo

 

full ngs panel

Complete genomic report with treatment exposure and clinical outcomes

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses

Histology

Classification into multiple categories

Enriched Data

Request a Demo

 

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI-Enriched Insights

Request a Demo

 

Cancer Subtype

Cancer type when ICD code is unknown

ECOG

Predict oft-missing performance score

Metastatic Status

Impute missing data from unstructured notes

Date of Initial Dx

Impute index event

EGFR Status

Impute specific gene mutation

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

prostate cancer

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

prostate research study

Treatment Patterns and Effectiveness in mCRPC

Treatments for metastatic castrate-resistant prostate cancer are not well understood. This study examined treatment patterns, sequencing, and outcomes in patients receiving second- and third-line treatment after first-line Docetaxel. 

See Full Study
Methods

Retrospective Observational Study

Analysis
  • Treatment patterns
  • Clinical effectiveness
  • Progression-free survival
  • Overall survival
Patient Features
  • Patients who progressed after line 1 Docetaxel
  • Received line 2 Cabazitaxel (DC), Abiraterone (DA) or other therapy (DO)
Results

284

Eligible patients

Patients taking Line 2 treatments after Line 1:

0

Patients receiving DC in line 2 received Abiraterone in Line 3

0

Abiraterone (DA)

Results
Increased risk of death in line 2 for DA compared to DC
0%

Patients receiving DC in line 2
received Abiraterone in Line 3


0%

Patients receiving DA in line 2
received Cabazitaxel in Line 3

Patients taking Line 2 treatments after Line 1 Docetaxel:

0

out of 284
Cabazitaxel (DC) 

0

out of 284
Abiraterone (DA) 

0

out of 284
Other therapy (DO) 

Conclusion

Shorter survival from line 2 for DA compared to DC. Results show that Cabazitaxel may not have been used optimally in the advanced disease setting.

Journal of Community and Supportive Oncology, 2014

Request a Demo